You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華蘭生物(002007.SZ):控股子公司對四價流感疫苗產品價格進行調整
格隆匯 06-05 11:48

格隆匯6月5日丨華蘭生物(002007.SZ)公佈,為提高流感疫苗的可及性,提升公司產品市場競爭力和市場佔有率,減輕人民羣眾和政府的經濟負擔,承擔企業社會責任,結合目前市場情況,經華蘭生物工程股份有限公司控股子公司華蘭生物疫苗股份有限公司認真研究論證,決定自2024年6月5日起對四價流感疫苗產品價格進行調整:

1、四價流感病毒裂解疫苗(成人劑型、預充式0.5ml/支)調整至88元/支;

2、四價流感病毒裂解疫苗(成人劑型、西林瓶0.5ml/瓶)調整至85元/瓶;

3、四價流感病毒裂解疫苗(兒童劑型、預充式0.25ml/支)調整至128元/支。

上述價格均未包含儲存運輸費,若部分地區收取疫苗儲存運輸費,掛網價格則根據儲存運輸費相應上調。

本次價格調整預計對公司四價流感疫苗銷售收入產生不利影響,對公司業績的影響最終以公司披露的定期報吿為準。從長遠來看,價格降低有利於刺激流感疫苗市場需求的增長,進一步提升流感疫苗接種率,擴大市場規模,帶來以價換量的市場機遇。下一步公司將通過加強內部費用控制,努力提升銷量等手段消化降價帶來的壓力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account